Preliminary results with administration of recombinant human erythropoietin in sickle cell/beta-thalassemia patients during pregnancy. (opens new window)

Bourantas K, Makrydimas G, Georgiou J, Tsiara S, Lolis D.

Źródło‎: Eur J Haematol 1996;56(5):326-8.

Indeks‎: PubMed 8641410

https://www.ncbi.nlm.nih.gov/pubmed/8641410 (opens new window)

On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease. (opens new window)

el-Hazmi MA, al-Momen A, Kandaswamy S, Huraib S, Harakati M, al-Mohareb F, Warsy AS.

Źródło‎: Acta Haematol 1995;94(3):128-34.

Indeks‎: PubMed 7502628

https://www.ncbi.nlm.nih.gov/pubmed/7502628 (opens new window)

Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. (opens new window)

Little JA, McGowan VR, Kato GJ, Partovi KS, Feld JJ, Maric I, Martyr S, Taylor JG 6th, Machado RF, Heller T, Castro O, Gladwin MT.

Źródło‎: Haematologica 2006;91(8):1076-83.

Indeks‎: PubMed 16885048

https://www.ncbi.nlm.nih.gov/pubmed/16885048 (opens new window)

Use of erythropoietin in a pregnant Jehovah's Witness with sickle-cell disease. (opens new window)

Tan TL, Ahmad H, Jhavar R, Patel R, Harrison C, Oteng-Ntim E.

Źródło‎: J Obstet Gynaecol 2007;27(1):82-3.

Indeks‎: PubMed 17365469

DOI‎: 10.1080/01443610601062739

https://www.ncbi.nlm.nih.gov/pubmed/17365469 (opens new window)

The use of barbiturate coma as salvage therapy in a postoperative Jehovah's Witness patient with life-threatening anemia. (opens new window)

Wang SW, Badami CD, Deitch EA.

Źródło‎: Am Surg 2009;75(12):1175-8.

Indeks‎: PubMed 19999907

https://www.ncbi.nlm.nih.gov/pubmed/19999907 (opens new window)